MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1

Apoptosis

Volumn 18, Issue 7, 2013, Pages 851-860

  Azijli, Kaamar ^a,c   Yuvaraj, Saravanan ^a   Van Roosmalen, Ingrid ^b   Flach, Koen ^c   Giovannetti, Elisa ^c   Peters, Godefridus J ^c   De Jong, Steven ^a   Kruyt, Frank A E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Combination therapy; Kinases; Lung cancer; TRAIL

Indexed keywords

CASPASE 8; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN MCL 1; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE 1; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 8; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; INDOLES; LUNG NEOPLASMS; MAP KINASE KINASE 4; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NUCLEAR PORE COMPLEX PROTEINS; ORGAN SPECIFICITY; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEOLYSIS; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84878729789     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-013-0829-3     Document Type: Article

References (44)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277-300
2. Blackstock AW, Govindan R (2007) Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer. J Clin Oncol 25:4146-4152
3. Lu C, Lee JJ, Komaki R, Herbst RS, Feng L, Evans WK et al (2010) Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst 102:859-865
4. Falschlehner C, Emmerich CH, Gerlach B, Walczak H (2007) TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 39:1462-1475
5. Gonzalvez F, Ashkenazi A (2010) New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 29:4752-4765
6. Johnstone RW, Frew AJ, Smyth MJ (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8:782-798
7. Hoogwater FJ, Nijkamp MW, Smakman N, Steller EJ, Emmink BL, Westendorp BF et al (2010) Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. Gastroenterology 138:2357-2367
8. Ishimura N, Isomoto H, Bronk SF, Gores GJ (2006) Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 290:G129-G136
9. Azijli K, Yuvaraj S, Peppelenbosch MP, Wurdinger T, Dekker H, Joore J et al (2012) Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3 dependent invasion in resistant non-small cell lung cancer cells. J Cell Sci. doi: 10.1242/jcs.109587
10. Karacay B, Sanlioglu S, Griffith TS, Sandler A, Bonthius DJ (2004) Inhibition of the NF-kappaB pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells. Cancer Gene Ther 11:681-690
11. Kim YS, Schwabe RF, Qian T, Lemasters JJ, Brenner DA (2002) TRAIL-mediated apoptosis requires NF-kappaB inhibition and the mitochondrial permeability transition in human hepatoma cells. Hepatology 36:1498-1508
12. Secchiero P, Gonelli A, Carnevale E, Milani D, Pandolfi A, Zella D et al (2003) TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 107:2250-2256
13. Thiefes A, Wolter S, Mushinski JF, Hoffmann E, ttrich-Breiholz O, Graue N et al (2005) Simultaneous blockade of NFkappaB, JNK, and p38 MAPK by a kinase-inactive mutant of the protein kinase TAK1 sensitizes cells to apoptosis and affects a distinct spectrum of tumor necrosis factor [corrected] target genes. J Biol Chem 280:27728-27741
14. Vaculova A, Hofmanova J, Soucek K, Kozubik A (2006) Different modulation of TRAIL-induced apoptosis by inhibition of pro-survival pathways in TRAIL-sensitive and TRAIL-resistant colon cancer cells. FEBS Lett 580:6565-6569
15. Weldon CB, Parker AP, Patten D, Elliott S, Tang Y, Frigo DE et al (2004) Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling. Int J Oncol 24:1473-1480
16. Zhang XD, Borrow JM, Zhang XY, Nguyen T, Hersey P (2003) Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene 22:2869-2881
17. Mathews ST, Plaisance EP, Kim T (2009) Imaging systems for westerns: chemiluminescence vs. infrared detection. Methods Mol Biol 536:499-513
18. Brummelkamp TR, Bernards R, Agami R (2002) Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2:243-247
19. van Leuken R, Clijsters L, van ZW, Lim D, Yao X, Wolthuis RM et al (2009) Polo-like kinase-1 controls Aurora A destruction by activating APC/C-Cdh1. PLoS ONE 4:e5282
20. Giovannetti E, Zucali PA, Assaraf YG, Leon LG, Smid K, Alecci C et al (2011) Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. Br J Cancer 105:1542-1553
21. Voortman J, Resende TP, Abou El Hassan MA, Giaccone G, Kruyt FA (2007) TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther 6:2103-2112
22. Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D et al (2005) Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem 280:40599-40608
23. Krishna M, Narang H (2008) The complexity of mitogen-activated protein kinases (MAPKs) made simple. Cell Mol Life Sci 65:3525-3544
24. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W et al (2001) SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 98:13681-13686
25. Young PR, McLaughlin MM, Kumar S, Kassis S, Doyle ML, McNulty D et al (1997) Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J Biol Chem 272:12116-12121
26. Wang Z, Canagarajah BJ, Boehm JC, Kassisa S, Cobb MH, Young PR et al (1998) Structural basis of inhibitor selectivity in MAP kinases. Structure 6:1117-1128
27. Degterev A, Hitomi J, Germscheid M, Ch'en IL, Korkina O, Teng X et al (2008) Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 4:313-321
28. Ferreira CG, Span SW, Peters GJ, Kruyt FA, Giaccone G (2000) Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res 60:7133-7141
29. Son JK, Varadarajan S, Bratton SB (2010) TRAIL-activated stress kinases suppress apoptosis through transcriptional upregulation of Mcl-1. Cell Death Differ 17:1288-1301
30. Trouillas M, Saucourt C, Duval D, Gauthereau X, Thibault C, Dembele D et al (2008) Bcl2, a transcriptional target of p38alpha, is critical for neuronal commitment of mouse embryonic stem cells. Cell Death Differ 15:1450-1459
31. Stegehuis JH, de Wilt LH, de Vries EG, Groen HJ, de Jong S, Kruyt FA (2010) TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives. Drug Resist Updat 13:2-15
32. Zhang L, Fang B (2005) Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12:228-237
33. Cargnello M, Roux PP (2011) Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 75:50-83
34. Festjens N, Vanden Berghe T, Cornelis S, Vandenabeele P (2007) RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ 14:400-410
35. Lin Y, Devin A, Rodriguez Y, Liu ZG (1999) Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. Genes Dev 13:2514-2526
36. Martinon F, Holler N, Richard C, Tschopp J (2000) Activation of a pro-apoptotic amplification loop through inhibition of NF-kappaB-dependent survival signals by caspase-mediated inactivation of RIP. FEBS Lett 468:134-136
37. Lin Y, Devin A, Cook A, Keane MM, Kelliher M, Lipkowitz S et al (2000) The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Mol Cell Biol 20:6638-6645
38. Thomas LW, Lam C, Edwards SW (2010) Mcl-1; the molecular regulation of protein function. FEBS Lett 584:2981-2989
39. Zhong Q, Gao W, Du F, Wang X (2005) Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 121:1085-1095
40. Domina AM, Vrana JA, Gregory MA, Hann SR, Craig RW (2004) MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 23:5301-5315
41. Kodama Y, Taura K, Miura K, Schnabl B, Osawa Y, Brenner DA (2009) Antiapoptotic effect of c-Jun N-terminal kinase-1 through Mcl-1 stabilization in TNF-induced hepatocyte apoptosis. Gastroenterology 136:1423-1434
42. Corazza N, Jakob S, Schaer C, Frese S, Keogh A, Stroka D et al (2006) TRAIL receptor-mediated JNK activation and Bim phosphorylation critically regulate Fas-mediated liver damage and lethality. J Clin Invest 116:2493-2499
43. Bogoyevitch MA, Ngoei KR, Zhao TT, Yeap YY, Ng DC (2010) c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges. Biochim Biophys Acta 1804:463-475
44. Mahalingam D, Keane M, Pirianov G, Mehmet H, Samali A, Szegezdi E (2009) Differential activation of JNK1 isoforms by TRAIL receptors modulate apoptosis of colon cancer cell lines. Br J Cancer 100:1415-1424